When do you consider discontinuing disease modifying therapies for multiple sclerosis?  

Certainly, age is increasingly being defined as a factor that influences disease evolution. There are some articles that suggest 55 years might be a 'turning point' to discontinue disease modifying therapies but my preference, particularly when there is no radiological or clinical worsening over the...

Our current disease-modifying therapies are most effective at preventing relapses, the development of new T2 lesions, and disability related to relapses. We know that relapses and new T2 lesions (from demyelinating diseases) decrease with age. Unfortunately, there is not one chronological age that f...